Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Nao Fujimori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4286-8804; OpenAlex author ID A5024065137. Sources: OpenAlex.

Their work

Papers
23 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
87
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: 5 papers · 2024: 2 papers · 2025: 4 papers · 2026: 4 papers

Papers 23

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response heterogeneity. Co-author DOI 10.1016/j.clnu.2026.106581↗
  3. Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41388-025-03633-4↗
  4. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  5. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  6. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.108958↗
  7. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  8. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  9. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. First author DOI 10.1007/s00535-024-02103-0↗
  10. Pancreatic cancer-related diabetes mellitus: A retrospective investigation of clinical characteristics and relationship with the prognosis Co-author DOI 10.21203/rs.3.rs-4088010/v1↗
  11. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-023-05591-2↗
  12. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  13. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy … Co-author DOI 10.1016/j.ejrad.2023.110756↗
  14. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  15. Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospe… First author DOI 10.1111/ajco.13903↗
  16. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. First author DOI 10.1007/s12672-021-00462-1↗
  17. What is the best modality for diagnosing pancreatic cancer? Co-author DOI 10.1111/den.14283↗
  18. Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. Co-author DOI 10.1186/s12885-022-10207-0↗
  19. Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic… First author DOI 10.3390/jcm11175084↗
  20. Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1. First author DOI 10.1007/s12328-020-01234-0↗
  21. Colonic varices: a rare complication of pancreatic cancer. First author DOI 10.1007/s12328-020-01225-1↗
  22. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
  23. Paclitaxel-based chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy failure: a case series of 5 patients. Co-author DOI 10.1159/000334704↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Ogawa · 12 shared papers, 2020–2026 · strength 2.15
  2. Masatoshi Murakami · 9 shared papers, 2020–2026 · strength 1.54
  3. Kohei Nakata · 8 shared papers, 2019–2025 · strength 1.27
  4. Katsuhito Teramatsu · 7 shared papers, 2020–2026 · strength 1.16
  5. Kazuhide Matsumoto · 7 shared papers, 2020–2026 · strength 1.16
  6. Akihisa Ohno · 6 shared papers, 2021–2026 · strength 1.02
  7. Toshiya Abe · 4 shared papers, 2022–2025 · strength 0.71
  8. Naoki Ikenaga · 4 shared papers, 2022–2025 · strength 0.71
  9. Kousei Ishigami · 4 shared papers, 2022–2025 · strength 0.67
  10. Masafumi Nakamura · 4 shared papers, 2019–2025 · strength 0.67
  11. Satoshi Kobayashi · 4 shared papers, 2023–2026 · strength 0.64
  12. Masafumi Ikeda · 4 shared papers, 2023–2026 · strength 0.64
  13. Masato Ozaka · 4 shared papers, 2023–2026 · strength 0.64
  14. Junji Furuse · 4 shared papers, 2023–2026 · strength 0.64
  15. Makoto Ueno · 4 shared papers, 2023–2026 · strength 0.64
  16. Masafumi Nakamura · 4 shared papers, 2021–2023 · strength 0.55
  17. Nobuhiro Fujita · 3 shared papers, 2023–2025 · strength 0.54
  18. Yoshinao Oda · 4 shared papers, 2019–2023 · strength 0.52
  19. Yukiko Takayama · 3 shared papers, 2023–2026 · strength 0.52
  20. Noboru Ideno · 3 shared papers, 2022–2025 · strength 0.52
  21. Takuji Okusaka · 3 shared papers, 2023–2026 · strength 0.45
  22. Akiko Todaka · 3 shared papers, 2023–2025 · strength 0.44
  23. Yoshinao Oda · 2 shared papers, 2024–2026 · strength 0.41
  24. Yusuke Sano · 2 shared papers, 2025–2026 · strength 0.40
  25. Masashi Kanai · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.